Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-10-23 Regulatory Filings
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data
Regulatory Filings Classification · 100% confidence The document is a press release issued by Egetis Therapeutics regarding a regulatory update from the FDA concerning the rolling NDA submission for their drug Emcitate. It details the outcome of a pre-NDA meeting, future submission timelines, and clinical trial status. It is a standard corporate regulatory announcement (RNS) that provides material information to the market, fitting the 'Regulatory Filings' category as it does not fall into specific categories like earnings releases or financial reports.
2025-10-23 English
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a 'directed share issue' by Egetis Therapeutics. It details the number of new shares issued, the subscription price, the total proceeds raised (SEK 183 million), the purpose of the funds, and the impact on share capital and dilution. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific capital-raising event involving the issuance of new shares.
2025-10-02 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående till 183 miljoner kronor
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a successful directed share issue (nyemission) by Egetis Therapeutics AB. It details the number of shares issued, the subscription price, the total capital raised, the purpose of the funds, and the involvement of institutional investors. This falls under the category of announcements regarding new share issues or capital changes.
2025-10-02 Swedish
Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares
Capital/Financing Update Classification · 100% confidence The document is a press release announcing Egetis Therapeutics' intention to conduct a 'directed share issue' (a private placement) to institutional investors. It details the purpose of the capital raise, the appointment of a bookrunner, and the legal disclaimers associated with the offering. This falls squarely under the definition of a capital/financing update, as it describes a specific fundraising activity and changes to the company's capital structure.
2025-10-02 English
Egetis Therapeutics avser att genomföra en riktad nyemission av högst 10 procent av utestående stamaktier
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Egetis Therapeutics announcing their intention to conduct a 'directed new share issue' (riktad nyemission) via an accelerated bookbuilding process. This is a classic capital raising announcement. According to the filing definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category. It is not a report publication announcement (RPA) because it is the primary announcement of the transaction itself, not a notice about a separate report.
2025-10-02 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report titled 'Halvårsrapport, januari-juni 2025' (Half-year report, January-June 2025). It contains detailed financial tables (income, cash flow, balance sheet items), management commentary ('VD har ordet'), business updates, and pipeline information. It is clearly an interim financial report for the first half of the fiscal year, not an announcement of a report or a standalone audit. H1 2025
2025-08-21 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.